MAZE (Maze Therapeutics) EBIT: $-130.84 Mil (TTM As of Mar. 2026)


MAZE Maze Therapeutics Inc MAZE
14 GF Score
Price $27.03
! 2 Warning Signs
View Full Analysis

What is Maze Therapeutics EBIT?

Maze Therapeutics MAZE +1.31% 14 EBIT is $-130.84 Mil as of Mar. 2026. GuruFocus rates MAZE with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Maze Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-23.34 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-130.84 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Maze Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 was -177.91%. Maze Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -310.57%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Maze Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -10.86%.

Maze Therapeutics  (NAS:MAZE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Maze Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-106.212 * ( 1 - 0% )/( (63.058 + 56.345)/ 2 )
=-106.212/59.7015
=-177.91 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=397.127 - 6.908 - ( 341.917 - max(0, 22.556 - 349.717+341.917))
=63.058

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=419.71 - 10.983 - ( 352.382 - max(0, 21.236 - 379.779+352.382))
=56.345

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Maze Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-93.368/( ( (25.16 + max(-9.961, 0)) + (23.967 + max(10.999, 0)) )/ 2 )
=-93.368/( ( 25.16 + 34.966 )/ 2 )
=-93.368/30.063
=-310.57 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 7.8) - (6.908 + 0 + 10.853)
=-9.961

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(20 + 0 + 7.397) - (10.983 + 0 + 5.415)
=10.999

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Maze Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-130.84/1204.272
=-10.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maze Therapeutics EBIT Related Terms

Maze Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for Maze Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maze Therapeutics EBIT Chart

Maze Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EBIT
-111.03 -98.55 57.59 -142.90

Maze Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.79 -36.47 -32.97 -38.06 -23.34

MAZE vs FTRE, ARDX, MBX: EBIT Comparison

For the Biotechnology subindustry, Maze Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Maze Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maze Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Maze Therapeutics's EV-to-EBIT falls into.


MAZE
14GF Score
Maze Therapeutics Inc MAZE
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maze Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-130.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-130.84 Mil mean?
Maze Therapeutics (MAZE) has a EBIT of $-130.84 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Maze Therapeutics.
Is Maze Therapeutics' EBIT too high?
Maze Therapeutics' current EBIT is $-130.84 Mil. Overall, Maze Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Maze Therapeutics' EBIT compare to FTRE and ARDX?
Maze Therapeutics' EBIT of $-130.84 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Maze Therapeutics. Maze Therapeutics's current EBIT is $-130.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maze Therapeutics stock overvalued right now?
Maze Therapeutics (MAZE) has a current EBIT of $-130.84 Mil. The current EBIT is $-130.84 Mil. Maze Therapeutics' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Maze Therapeutics (MAZE), the current EBIT is $-130.84 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Maze Therapeutics Business Description

Address 171 Oyster Point boulevard, Suite 300, South San Francisco, CA, USA, 94080
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
14GF Score

Get the complete analysis for MAZE

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.03
Price